Published in Cold Spring Harb Perspect Med on March 01, 2012
Fetal regulatory T cells and peripheral immune tolerance in utero: implications for development and disease. Am J Reprod Immunol (2013) 1.04
Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. J Autoimmun (2014) 0.87
TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions. J Virol (2012) 0.87
Pathological conditions re-shape physiological Tregs into pathological Tregs. Burns Trauma (2015) 0.83
DCIR2+ cDC2 DCs and Zbtb32 Restore CD4+ T-Cell Tolerance and Inhibit Diabetes. Diabetes (2015) 0.82
Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells. Transl Res (2014) 0.78
A SNP in the Immunoregulatory Molecule CTLA-4 Controls mRNA Splicing In Vivo but Does Not Alter Diabetes Susceptibility in the NOD Mouse. Diabetes (2015) 0.77
Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials. Pediatr Diabetes (2013) 0.77
Autoimmune diabetes is suppressed by treatment with recombinant human tissue Kallikrein-1. PLoS One (2014) 0.76
A missing PD-L1/PD-1 coinhibition regulates diabetes induction by preproinsulin-specific CD8 T-cells in an epitope-specific manner. PLoS One (2013) 0.76
Exploring the induction of preproinsulin-specific Foxp3(+) CD4(+) Treg cells that inhibit CD8(+) T cell-mediated autoimmune diabetes by DNA vaccination. Sci Rep (2016) 0.75
Deficiency of Nuclear Factor-κB c-Rel Accelerates the Development of Autoimmune Diabetes in NOD Mice. Diabetes (2016) 0.75
Alteration of the thymic T cell repertoire by rotavirus infection is associated with delayed type 1 diabetes development in non-obese diabetic mice. PLoS One (2013) 0.75
Type 1 Diabetes Mellitus Donor Mesenchymal Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro. Stem Cells Transl Med (2016) 0.75
Vitamin A: a missing link in diabetes? Diabetes Manag (Lond) (2015) 0.75
Congenic mapping identifies a novel Idd9 subregion regulating type 1 diabetes in NOD mice. Immunogenetics (2016) 0.75
Beta-cell specific autoantibodies: Are they just an indicator of type 1 diabetes? Curr Diabetes Rev (2016) 0.75
Presentation of Autoantigen in Peripheral Lymph Nodes Is Sufficient for Priming Autoreactive CD8(+) T Cells. Front Immunol (2017) 0.75
B cells in type 1 diabetes mellitus and diabetic kidney disease. Nat Rev Nephrol (2017) 0.75
Peripheral Autoimmune Regulator Induces Exhaustion of CD4(+) and CD8(+) Effector T Cells to Attenuate Autoimmune Diabetes in Non-Obese Diabetic Mice. Front Immunol (2017) 0.75
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
The impact of microRNAs on protein output. Nature (2008) 32.39
Widespread changes in protein synthesis induced by microRNAs. Nature (2008) 31.44
IL-17 and Th17 Cells. Annu Rev Immunol (2009) 23.02
Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature (2010) 22.04
NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A (2006) 21.58
An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol (2003) 19.16
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet (2007) 19.04
Requirement of bic/microRNA-155 for normal immune function. Science (2007) 16.24
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 15.44
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 15.27
A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med (2007) 15.17
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol (2006) 14.33
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 13.00
CTLA-4 control over Foxp3+ regulatory T cell function. Science (2008) 12.67
Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature (2008) 12.45
Regulation of the germinal center response by microRNA-155. Science (2007) 12.25
A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet (2004) 12.25
Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem (2010) 12.06
Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science (1999) 11.96
A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol (2005) 11.48
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 10.16
Foxp3-dependent programme of regulatory T-cell differentiation. Nature (2007) 9.48
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65
The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol (2009) 8.32
Plasticity of CD4+ T cell lineage differentiation. Immunity (2009) 8.08
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00
Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med (2005) 7.87
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44
MicroRNA control in the immune system: basic principles. Cell (2009) 7.16
Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature (2007) 7.04
Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med (2002) 7.00
The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 6.71
Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature (2009) 6.65
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature (2002) 6.58
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet (2005) 6.48
CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science (2009) 6.14
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev (2006) 6.08
Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science (2010) 6.06
Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 5.88
A role for Dicer in immune regulation. J Exp Med (2006) 5.81
Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature (2007) 5.81
GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med (2008) 5.74
Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet (2007) 5.68
Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell (2008) 5.53
CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity (2002) 5.38
T cell lineage choice and differentiation in the absence of the RNase III enzyme Dicer. J Exp Med (2005) 5.26
Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature (2010) 5.16
Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity (2009) 5.10
Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol (2003) 5.07
Stability of the regulatory T cell lineage in vivo. Science (2010) 4.89
Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest (2009) 4.74
Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med (2008) 4.68
MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity (2010) 4.65
Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell (2010) 4.57
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol (2003) 4.56
TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 4.40
Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet (2005) 4.36
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet (2011) 4.30
Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA (2007) 4.29
Impaired Fas response and autoimmunity in Pten+/- mice. Science (1999) 4.25
Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev (2011) 4.15
Deletional tolerance mediated by extrathymic Aire-expressing cells. Science (2008) 4.10
Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nat Immunol (2006) 3.85
miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med (2011) 3.78
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A (1994) 3.77
The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet (1997) 3.70
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
Dicer-dependent microRNA pathway safeguards regulatory T cell function. J Exp Med (2008) 3.70
T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell Immunol (2002) 3.57
Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity (2008) 3.48
The RNAseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. J Exp Med (2008) 3.45
Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol (2009) 3.42
alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med (1998) 3.34
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin Exp Immunol (2010) 3.17
Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest (2004) 3.17
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
Oral tolerance. Immunol Rev (2011) 3.03
Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med (2003) 2.94
CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol (1997) 2.89
2008 Update from the Collaborative Islet Transplant Registry. Transplantation (2008) 2.84
Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol (2006) 2.79
The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes (2008) 2.77
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
NOD mouse colonies around the world--recent facts and figures. Immunol Today (1993) 2.53
Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52
Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol (2009) 2.51
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature (2008) 12.45
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 8.00
Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol (2005) 7.44
The NOD mouse: a model of immune dysregulation. Annu Rev Immunol (2005) 6.71
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20
Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature (2007) 4.94
Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med (2008) 4.68
TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 4.40
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol (2003) 3.86
Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med (2005) 3.70
Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med (2012) 3.40
Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol (2004) 3.18
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity (2005) 3.07
CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol (2007) 3.06
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol (2009) 2.93
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev (2008) 2.86
NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity (2004) 2.80
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity (2003) 2.57
Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant (2004) 2.55
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes (2008) 2.52
Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity (2013) 2.41
Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol (2011) 2.39
Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology (2007) 2.33
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30
Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol (2013) 2.13
Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev (2006) 2.13
CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med (2008) 2.07
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev (2009) 2.00
Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest (2003) 1.95
Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 1.90
Cell-based therapeutics: the next pillar of medicine. Sci Transl Med (2013) 1.83
Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol (2006) 1.75
Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest (2004) 1.74
How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes (2011) 1.74
Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol (2005) 1.73
Murine pancreatic islet isolation. J Vis Exp (2007) 1.68
Regulated beta-cell regeneration in the adult mouse pancreas. Diabetes (2007) 1.67
Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol (2005) 1.67
A resource for the conditional ablation of microRNAs in the mouse. Cell Rep (2012) 1.66
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest (2010) 1.63
Notch 1 signaling regulates peripheral T cell activation. Immunity (2004) 1.61
Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Semin Immunol (2006) 1.55
IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A (2012) 1.54
The microRNA cluster miR-17∼92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. Nat Immunol (2013) 1.50
Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes (2006) 1.49
Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol (2011) 1.49
CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol (2011) 1.45
Production of α-galactosylceramide by a prominent member of the human gut microbiota. PLoS Biol (2013) 1.42
Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One (2011) 1.39
Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol (2005) 1.38
Immune therapy and β-cell death in type 1 diabetes. Diabetes (2013) 1.33
Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med (2013) 1.29
Transplantation of pancreatic islets into the kidney capsule of diabetic mice. J Vis Exp (2007) 1.28
Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol (2002) 1.28
Regulatory T cells: stability revisited. Trends Immunol (2011) 1.27
The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med (2011) 1.26
Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.26
When ligand becomes receptor--tolerance via B7 signaling on DCs. Nat Immunol (2002) 1.25
Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol (2003) 1.25
Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol (2011) 1.25
CTLA-4 and tolerance: the biochemical point of view. Immunol Res (2003) 1.24
Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol (2013) 1.24
The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol (2002) 1.24
Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation (2010) 1.23
Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2003) 1.20
T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol (2009) 1.16
Inability to induce tolerance through direct antigen presentation. Am J Transplant (2002) 1.16
Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol (2008) 1.14
MicroRNA regulation of T-cell differentiation and function. Immunol Rev (2013) 1.13
The immune tolerance network: a new paradigm for developing tolerance-inducing therapies. J Allergy Clin Immunol (2002) 1.13
Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. J Immunol (2011) 1.12
Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol (2007) 1.11
Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes (2010) 1.10
MicroRNA 10a marks regulatory T cells. PLoS One (2012) 1.09
Achieving antigen-specific tolerance in diabetes: regulating specifically. Int Rev Immunol (2005) 1.09
CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Nat Immunol (2003) 1.06
microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol (2013) 1.05
B7-independent inhibition of T cells by CTLA-4. J Immunol (2005) 1.05
Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest (2006) 1.05
Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. J Immunol (2005) 1.04
Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One (2010) 1.03
Mechanisms of tolerance. Immunol Rev (2011) 1.01
B cell depletion: a novel therapy for autoimmune diabetes? J Clin Invest (2007) 1.00
Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease. Eur J Immunol (2007) 1.00